Ani Pharmaceuticals (ANIP) Cost of Revenue (2012 - 2026)

Ani Pharmaceuticals has disclosed Cost of Revenue across 15 years of filings, most recently posting $93.6 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $93.6 million, up 28.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $361.9 million (up 32.02% YoY), and the FY2025 annual result was $341.3 million, up 36.41% from the prior year.
• Cost of Revenue came in at $93.6 million for Q1 2026 at Ani Pharmaceuticals, down from $100.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $100.3 million in Q4 2025 to a low of $32.9 million in Q3 2022.
• The 5-year median for Cost of Revenue is $53.4 million (2023), against an average of $59.1 million.
• Peak annual rise in Cost of Revenue reached 71.48% in 2022, while the deepest fall reached 7.16% in 2022.
• Ani Pharmaceuticals' Cost of Revenue stood at $36.3 million in 2022, then surged by 47.06% to $53.4 million in 2023, then jumped by 50.28% to $80.3 million in 2024, then advanced by 24.9% to $100.3 million in 2025, then fell by 6.67% to $93.6 million in 2026.
• The last three Cost of Revenue figures came in at $93.6 million (Q1 2026), $100.3 million (Q4 2025), and $93.4 million (Q3 2025), per Business Quant data.